Evidence map›Paper›PMID 33520653›Full record

ArticleMetabolic engineering communications2021

Engineered cyanobacteria with additional overexpression of selected Calvin-Benson-Bassham enzymes show further increased ethanol production.

Stamatina Roussou, Alessia Albergati, Feiyan Liang, Peter Lindblad

Open access · goldAbstract read
In one paragraph

Article in Metabolic engineering communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. EnhancedMarine drugs · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Rewiring carbon flow inFrontiers in microbiology · 2023
    Article
  10. Introduction to Cyanobacteria.Advances in biochemical engineering/biotechnology · 2023
    Article
  11. Impact of the carbon flux regulator proteinFrontiers in microbiology · 2023
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Stamatina RoussouMicrobial Chemistry, Department of Chemistry-Ångström, Uppsala University, Box 523, SE-751 20, Uppsala, Sweden.
Alessia AlbergatiMicrobial Chemistry, Department of Chemistry-Ångström, Uppsala University, Box 523, SE-751 20, Uppsala, Sweden.
Feiyan LiangMicrobial Chemistry, Department of Chemistry-Ångström, Uppsala University, Box 523, SE-751 20, Uppsala, Sweden.
Peter LindbladMicrobial Chemistry, Department of Chemistry-Ångström, Uppsala University, Box 523, SE-751 20, Uppsala, Sweden.
Uppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyanobacteria are one of the most promising microorganisms to produce biofuels and renewable chemicals due to their oxygenic autotrophic growth properties. However, to rely on photosynthesis, which is one of the main reasons for slow growth, low carbon assimlation rate and low production, is a bottleneck. To address this challenge, optimizing the Calvin-Benson-Bassham (CBB) cycle is one of the strategies since it is the main carbon fixation pathway. In a previous study, we showed that overexpression of either aldolase (FBA), transketolase (TK), or fructose-1,6/sedoheptulose-1,7-bisphosphatase (FBP/SBPase), enzymes responsible for RuBP regeneration and vital for controlling the CBB carbon flux, led to higher production rates and titers in ethanol producing strains of

Indexed as

Calvin-Benson-BasshamCarbon fixationCyanobacteriaEthanolFBAFBP/SBPaseTK

Identifiers

PMID33520653
PMCPMC7820548
OpenAlexW3120305025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.